Postimmunization with IFN-γ-secreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 4231-4238

  Badn, Wiaam ^a,b   Visse, Edward ^a   Darabi, Anna ^a   Smith, Karin Enell ^a   Salford, Leif G ^a   Siesjö, Peter ^a  

^a Department of Clinical Sciences   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 MERCAPTOETHYL)GUANIDINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; 2-MERCAPTOETHYLGUANIDINE; DRUG DERIVATIVE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; LYSINE; N(6) (1 IMINOETHYL)LYSINE; N(6)-(1-IMINOETHYL)LYSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BRAIN TUMOR; CANCER SURVIVAL; CELL COUNT; CONTROLLED STUDY; DRUG POTENTIATION; GLIOMA CELL; IMMUNIZATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; FISCHER 344 RAT; GLIOMA; IMMUNOLOGY; LYMPH NODE; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHYSIOLOGY; SECRETION; SPLEEN; SURVIVAL; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; GLIOMA; GUANIDINES; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; LYMPH NODES; LYSINE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, INBRED F344; SPLEEN; SURVIVAL; T-LYMPHOCYTES;

EID: 35748962307     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.4231     Document Type: Article

References (40)

1. Visse, E., P. Siesjö, B. Widegren, and H. O. Sjögren. 1999. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-γ, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther. 6: 37-44.
2. Chen, J. C., Y. Chen, J. M. Wu, Y. H. Su, K. F. Tai, and S. H. Tseng. 2006. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. Cancer Immunol. Immunother. 55: 873-883.
3. Smalley, K. S., P. A. Brafford, and M. Herlyn. 2005. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin. Cancer Biol. 15: 451-459.
4. Satoh, E., H. Naganuma, A. Sasaki, M. Nagasaka, H. Ogata, and H. Nukui. 1997. Effect of irradiation on transforming growth factor-β secretion by malignant glioma cells. J. Neurooncol. 33: 195-200.
5. Hishii, M., T. Nitta, H. Ishida, M. Ebato, A. Kurosu, H. Yagita, K. Sato, and K. Okumura. 1995. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 37: 1160-1166.
6. Buccoliero, A. M., A. Caldarella, C. F. Gheri, A. Taddei, M. Paglierani, M. Pepi, P. Mennonna, and G. L. Taddei. 2006. Inducible cyclooxygenase (COX-2) in glioblastoma- clinical and immunohistochemical (COX-2-VEGF) correlations. Clin. Neuropathol. 25: 59-66.
7. Zou, J.-P., L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, and G. M. Shearer. 1999. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162: 4882-4892.
8. Bronte, V., P. Serafini, A. Mazzoni, D. M. Segal, and P. Zanovello. 2003. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24: 302-306.
9. Munder, M., K. Eichmann, J. M. Morán, F. Centeno, G. Soler, and M. Modolell. 1999. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J. Immunol. 163: 3771-3777.
10. Zea, A. H., P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, et al. 2005. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65: 3044-3048.
11. Bronte, V., P. Serafini, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, D. M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170: 270-278.
12. Abe, K., M. Harada, K. Tamada, O. Ito, T. Li, and K. Nomoto. 1998. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol. Immunother. 45: 225-233.
13. Kusmartsev, S., and D. I. Gabrilovich. 2005. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J. Immunol. 174: 4880-4891.
14. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168: 689-695.
15. Niedbala, W., X. Q. Wei, C. Campbell, D. Thomson, M. Komai-Koma, and F. Y. Liew. 2002. Nitric oxide preferentially induces type 1 T cell differentiation by selectively up-regulating IL-12 receptor β2 expression via cGMP. Proc. Natl. Acad. Sci. USA 99: 16186-16191.
16. Ibiza, S., V. M. Victor, I. Boscá, A. Ortega, A. Urzainqui, J. E. O'Connor, F. Sánchez-Madrid, J. V. Esplugues, and J. M. Serrador. 2006. Endothelial nitric oxide synthase regulates T cell receptor signaling at the immunological synapse. Immunity 24: 753-765.
17. Worthington, J., H. O. McCarthy, E. Barrett, C. Adams, T. Robson, and D. G. Hirst. 2004. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J. Gene Med. 6: 673-680.
18. Keller, R., R. Keist, A. Wechsler, T. P. Leist, and P. H. van der Meide. 1990. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int. J. Cancer 46: 682-686.
19. Johansson, A. C., P. Hegardt, S. Janelidze, E. Visse, B. Widegren, and P. Siesjö. 2002. Enhanced expression of iNOS intratumorally and at the immunization site after immunization with IFNγ-secreting rat glioma cells. J. Neuroimmunol. 123: 135-143.
20. Hegardt, P., B. Widegren, L. Li, B. Sjögren, C. Kjellman, I. Sur, and H. O. Sjögren. 2001. Nitric oxide synthase inhibitor and IL-18 enhance the antitumor immune response of rats carrying an intrahepatic colon carcinoma. Cancer Immunol. Immunother. 50: 491-501.
21. Hegardt, P., B. Widegren, and H. O. Sjögren. 2000. Nitric-oxide-dependent systemic immunosuppression in animals with progressively growing malignant gliomas. Cell Immunol. 200: 116-127.
22. Koblish, H. K., C. A. Hunter, M. Wysocka, G. Trinchieri, and W. M. Lee. 1998. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188: 1603-1610.
23. Badn, W., S. Kalliomaki, B. Widegren, and H. O. Sjögren. 2006. Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin. Cancer Res. 12: 4714-4719.
24. Badn, W., P. Hegardt, M. A. Fellert, A. Darabi, M. Esbjornsson, K. E. Smith, S. Janelidze, L. G. Salford, E. Visse, and P. Siesjö. 2007. Inhibition of inducible nitric oxide synthase enhances anti-tumour immune responses in rats immunized with IFN-γ-secreting glioma cells. Scand. J. Immunol. 65: 289-297.
25. Szabó, C., G. Ferrer-Sueta, B. Zingarelli, G. J. Southan, A. L. Salzman, and R. Radi. 1997. Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J. Biol. Chem. 272: 9030-9036.
26. Zingarelli, B., S. Cuzzocrea, C. Szabó, and A. L. Salzman. 1998. Mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J. Pharmacol. Exp. Ther. 287: 1048-1055.
27. 6-(1-iminoethyl)lysine. J. Pharmacol. Exp. Ther. 295: 417-422.
28. 6-(1-iminoethyl)lysine. Biochemistry 37: 4844-4852.
29. Wolff, D. J., and A. Lubeskie. 1995. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch. Biochem. Biophys. 316: 290-301.
30. -) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol. Immunother. 37: 67-74.
31. + rat glioma. Cell Immunol. 165: 225-233.
32. 15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138.
33. Badn, W. H., P. Fellert, M. A. Darabi, A. Esbjörnsson, M. Smith, K. E. Janelidze, L. G. Salford, E. Visse, and P. Siesjö. 2006. Inhibition of inducible nitric oxide synthase enhances anti-tumor immune responses in rats immunized with IFN-γ secreting glioma cells. Scand. J. Immunol. 65: 289-297.
34. Thorvaldson, L., S. E. Johansson, P. Höglund, and S. Sandler. 2005. Impact of plastic adhesion in vitro on analysis of Th1 and Th2 cytokines and immune cell distribution from mice with multiple low-dose streptozotocin-induced diabetes. J. Immunol. Methods 307: 73-81.
35. Zingarelli, B., G. J. Southan, E. Gilad, M. O'Connor, A. L. Salzman, and C. Szabó. 1997. The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br. J. Pharmacol. 120: 357-366.
36. Samdani, A. F., E. B. Kuchner, L. Rhines, D. C. Adamson, C. Lawson, B. Tyler, H. Brem, V. L. Dawson, and T. M. Dawson. 2004. Astroglia induce cytotoxic effects on brain tumors via a nitric oxide-dependent pathway both in vitro and in vivo. Neurosurgery 54: 1231-1237.
37. Chen, C., W. H. Lee, L. Zhong, and C. P. Liu. 2006. Regulatory T cells can mediate their function through the stimulation of APCs to produce immunosuppressive nitric oxide. J. Immunol. 176: 3449-3460.
38. Szentistvanyi, I., C. S. Patlak, R. A. Ellis, and H. F. Cserr. 1984. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246: F835-F844.
39. + Tregs. J. Clin. Invest. 115: 2904-2913.
40. + T-cell responses to herpes simplex virus type 2-infected human dendritic cells. Viral Immunol. 18: 616-626.